Cargando…
Strategies of LncRNA DLX6-AS1 on Study and Therapeutics
Accumulating evidence has revealed the vital regulatory roles of lncRNA DLX6-AS1 in various tumors at pre-transcriptional, transcriptional, and post-transcriptional levels, which makes it a potential prognosis factor and therapeutic target. In addition, the presence of lncRNA DLX6-AS1 in the exosome...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198352/ https://www.ncbi.nlm.nih.gov/pubmed/35719380 http://dx.doi.org/10.3389/fgene.2022.871988 |
_version_ | 1784727595168825344 |
---|---|
author | Zhao, Yanyan Li, Pei |
author_facet | Zhao, Yanyan Li, Pei |
author_sort | Zhao, Yanyan |
collection | PubMed |
description | Accumulating evidence has revealed the vital regulatory roles of lncRNA DLX6-AS1 in various tumors at pre-transcriptional, transcriptional, and post-transcriptional levels, which makes it a potential prognosis factor and therapeutic target. In addition, the presence of lncRNA DLX6-AS1 in the exosomes of peripheral blood of patients with tumors may also contribute to it being a possible cancer-related biomarker. However, most literature studies are devoted to studying the effect of lncRNA DLX6-AS1 as a sponging molecule of miRNAs, the research of which is likely to get stuck into a dilemma. Literature studies published already have demonstrated an exciting cell malignant phenotype inhibition with the knockdown of lncRNA DLX6-AS1 in various tumor cell lines. With the comprehensive development of delivery systems, high-throughput sequencing, and aptamers, the problems of finding novel research methods and exploring the therapeutic options which are based on lncRNA DLX6-AS1 in vivo could come into a period to deal with. This review aims to summarize the research statuses of lncRNA DLX6-AS1, discuss other study methodologies and therapeutic strategies on it, which might be of help to the deep learning of lncRNA DLX6-AS1 and its application from basic to clinical research. |
format | Online Article Text |
id | pubmed-9198352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91983522022-06-16 Strategies of LncRNA DLX6-AS1 on Study and Therapeutics Zhao, Yanyan Li, Pei Front Genet Genetics Accumulating evidence has revealed the vital regulatory roles of lncRNA DLX6-AS1 in various tumors at pre-transcriptional, transcriptional, and post-transcriptional levels, which makes it a potential prognosis factor and therapeutic target. In addition, the presence of lncRNA DLX6-AS1 in the exosomes of peripheral blood of patients with tumors may also contribute to it being a possible cancer-related biomarker. However, most literature studies are devoted to studying the effect of lncRNA DLX6-AS1 as a sponging molecule of miRNAs, the research of which is likely to get stuck into a dilemma. Literature studies published already have demonstrated an exciting cell malignant phenotype inhibition with the knockdown of lncRNA DLX6-AS1 in various tumor cell lines. With the comprehensive development of delivery systems, high-throughput sequencing, and aptamers, the problems of finding novel research methods and exploring the therapeutic options which are based on lncRNA DLX6-AS1 in vivo could come into a period to deal with. This review aims to summarize the research statuses of lncRNA DLX6-AS1, discuss other study methodologies and therapeutic strategies on it, which might be of help to the deep learning of lncRNA DLX6-AS1 and its application from basic to clinical research. Frontiers Media S.A. 2022-06-01 /pmc/articles/PMC9198352/ /pubmed/35719380 http://dx.doi.org/10.3389/fgene.2022.871988 Text en Copyright © 2022 Zhao and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Zhao, Yanyan Li, Pei Strategies of LncRNA DLX6-AS1 on Study and Therapeutics |
title | Strategies of LncRNA DLX6-AS1 on Study and Therapeutics |
title_full | Strategies of LncRNA DLX6-AS1 on Study and Therapeutics |
title_fullStr | Strategies of LncRNA DLX6-AS1 on Study and Therapeutics |
title_full_unstemmed | Strategies of LncRNA DLX6-AS1 on Study and Therapeutics |
title_short | Strategies of LncRNA DLX6-AS1 on Study and Therapeutics |
title_sort | strategies of lncrna dlx6-as1 on study and therapeutics |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198352/ https://www.ncbi.nlm.nih.gov/pubmed/35719380 http://dx.doi.org/10.3389/fgene.2022.871988 |
work_keys_str_mv | AT zhaoyanyan strategiesoflncrnadlx6as1onstudyandtherapeutics AT lipei strategiesoflncrnadlx6as1onstudyandtherapeutics |